Shire clears development path for SHP465
This article was originally published in Scrip
Executive Summary
Shire has agreed an updated development pathway with the US FDA for its investigational attention-deficit/hyperactivity disorder (ADHD) drug, SHP465 (triple-bead mixed amphetamine salts) – a product which has hovered in regulatory limbo for years.